J.P. Morgan sees mid-cap defense firms like Kratos rebounding in the second half of 2025 amid Pentagon-driven tailwinds.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $28.00. The company’s shares closed yesterday a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

On Monday, Bernstein SocGen Group lowered the price target for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN) to $750 from $896, while maintaining an Outperform rating. This adjustment follows Regeneron ...

On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, and sharply reduced the stock’s price target to $662 from ...

Monday’s moves come after the S&P 500 closed out the month of May with a more than 6% gain, its best monthly performance ...

On Monday, Bernstein SocGen Group lowered the price target for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN) to $750 from $896, while maintaining an Outperform rating. This adjustment follows ...